# A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke

Study · id `cardio:ct-nct07742098` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07742098](<https://clinicaltrials.gov/study/NCT07742098>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07742098

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

## Technical summary

Registry record NCT07742098. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2028-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT07742098, source copy `cardio:ctgov-nct07742098-2026-08-03`, retrieved 2026-10-26)
- Planned start: 2026-10-31 (anticipated) (ClinicalTrials.gov record NCT07742098, source copy `cardio:ctgov-nct07742098-2026-08-03`, retrieved 2026-10-26)
- Primary completion: 2028-12-15 (anticipated) (ClinicalTrials.gov record NCT07742098, source copy `cardio:ctgov-nct07742098-2026-08-03`, retrieved 2026-10-26)
- Completion: 2028-12-15 (anticipated) (ClinicalTrials.gov record NCT07742098, source copy `cardio:ctgov-nct07742098-2026-08-03`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07742098-2026-08-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
- Acronym: ACT-IVATE
- Condition: Acute Ischemic Stroke
- Intervention (Drug): NTS-521
- Intervention (Other): Placebo Control
- Lead sponsor: NeuroTrauma Sciences, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 2b3da222cd2eac0e507cea1f4181a2ede254968fbe4f531bcecb5d46ef9dcec3
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
